CNCE
NASDAQConcert Pharmaceuticals Inc.
Website
News25/Ratings1
Latest news
25 items- SECSEC Form 15-12G filed by Concert Pharmaceuticals Inc.15-12G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)
- SECSEC Form EFFECT filed by Concert Pharmaceuticals Inc.EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)
- SECSEC Form EFFECT filed by Concert Pharmaceuticals Inc.EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)
- SECSEC Form EFFECT filed by Concert Pharmaceuticals Inc.EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)
- SECSEC Form EFFECT filed by Concert Pharmaceuticals Inc.EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)
- SECSEC Form SC TO-T/A filed by Concert Pharmaceuticals Inc. (Amendment)SC TO-T/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- SECSEC Form SC 14D9/A filed by Concert Pharmaceuticals Inc. (Amendment)SC 14D9/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- INSIDERSEC Form 4: Stuart Nancy sold $50,380 worth of shares (6,048 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 262,596 units (withholding obligation)4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
- INSIDERSEC Form 4: Munsie Jeffrey A sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 88,049 units to cover withholding tax4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
- INSIDERSEC Form 4: Cassella James V sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 173,061 units to satisfy withholding obligation4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
- INSIDERSEC Form 4: Becker Marc A. sold $31,337 worth of shares (3,762 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 123,863 units (for tax liability)4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
- NEWSConcert Pharmaceuticals Says FDA Determined That Deuruxolitinib Will Maintain Its Breakthrough Therapy Designation
- PRConcert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia AreataConcert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibitor, is being developed for the treatment of adult patients with moderate to severe alopecia areata. In light of the FDA approval of a different JAK inhibitor as the first treatment for alopecia areata, the FDA previously notified Concert that it was reviewing the Breakthrough Therapy designation previously granted for deuruxolitinib. At the FDA's request, Concert submitted additional clinical data an
- 13D/GSEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- 13D/GSEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- 13D/GSEC Form SC 13G filed by Concert Pharmaceuticals Inc.SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- 13D/GSEC Form SC 13G filed by Concert Pharmaceuticals Inc.SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- SECSEC Form SC 14D9 filed by Concert Pharmaceuticals Inc.SC 14D9 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- SECSEC Form SC TO-T filed by Concert Pharmaceuticals Inc.SC TO-T - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- SECSEC Form SC TO-C filed by Concert Pharmaceuticals Inc.SC TO-C - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- SECSEC Form SC TO-C filed by Concert Pharmaceuticals Inc.SC TO-C - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- INSIDERSEC Form 4: Stuart Nancy sold $110,220 worth of shares (13,200 units at $8.35) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 268,644 units (withholding tax)4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
- INSIDERSEC Form 4: Munsie Jeffrey A sold $70,917 worth of shares (8,493 units at $8.35) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 91,811 units (for withholding tax)4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
- INSIDERSEC Form 4: Cassella James V sold $84,385 worth of shares (10,106 units at $8.35) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 176,823 units (withholding tax)4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
- INSIDERSEC Form 4: Becker Marc A. sold $70,917 worth of shares (8,493 units at $8.35) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 127,625 units (for withholding tax)4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)